With our model, we were able to provide novel insights about the pathophysiology and treatment of GLUT1-DS, including reassessing KD mechanisms, the role of astrocytes in metabolic buffering, seizure mechanisms, as well as the potential effects of supplementary treatments involving redox restoration and glucose-sparing. This evidence concerns the gene SLC2A1 and Dravet syndrome.